Study proposes repurposed drug to treat COVID-19
The Hindu
The drug is now in Phase-II trials to evaluate efficacy, safety, tolerability to treat COVID-19 patients
A long wait for drugs to treat COVID-19 may come to a close, if Phase II trials of the drug niclosamide deliver positive results. The repurposed drug, an antihelminth originally used to treat tapeworm infection, was found to show promise in an exploratory study undertaken by Bengaluru-based National Centre for Biological Sciences (NCBS-TIFR) and Institute for Stem Cell Science and Regenerative Medicine (InSTEM) along with Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu. Based on the recommendations of this preliminary study, the drug is now under “multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients,” according to a press release of the Council of Scientific and Industrial Research (CSIR) dated July 5. Since the drug has been used in people earlier for tapeworm infection in adults as well as children, its safety profile is well established and the questions are more about its efficacy in treating COVID-19 and the dosage etc. Among those following the news about the novel coronavirus, it is well known that the spike protein of the receptor binding domain attaches itself to the ACE2 receptor present in the cell. This is a route the virus uses to enter the cell.More Related News